GS-US-417-0303: A Randomized, Double-blind, Placebo-and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotrexate (MTX) to Subjects with Moderately to Severly Active Rheumatoid Arthritis Who Are Naïve to MTX Therapy College of Medicine – Jacksonville

GS-US-417-0303: A Randomized, Double-blind, Placebo-and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotrexate (MTX) to Subjects with Moderately to Severly Active Rheumatoid Arthritis Who Are Naïve to MTX Therapy

The purpose of this study is to see if filgotinib can be useful to treat RA as single therapy or in combination with Methotrexate (MTX).

Gurjit S. Kaeley, M.B.B.S. (M.D.)
Medicine